Vikram Sudarsan
Strategy Head - Cipla New Ventures - Cipla USA @ Cipla
San Diego, United States
Vikram Sudarsan is a Series B investor at Cipla in San Diego focused on Medical and Health Care. Vikram Sudarsan is Strategy Head of Cipla New Ventures at Cipla USA since October 2013. Vikram is a versatile biotech pharma professional with deep expertise in the scientific and commercial aspects of drug development. Prior to joining Cipla, Vikram helped start IMS's new Transaction Advisory Practice – IMS Health Capital, Inc. as anEngagement Manager in Partnership. Prior to that Vikram helped establish and grow the Asset Valuation practice at PriceSpective, LLC before its sale to ICON Plc. At IMS and PriceSpective he built a differentiated risk-sharing based licensing, mergers & acquisitions business. Vikram led global teams to develop a deep understanding of assets value and potential before advising clients on transactions. Vikram has led due diligence projects for several of the top twenty pharma companies on the buy-side and strategy development projects for numerous small biotech clients on the sell-side. Vikram is an INLAKS scholar. Vikram has a Ph.D. in Genetics from University of Sheffield, UK and carried out his doctoral research at the University of Cambridge. Vikram has a Post Doctorate in Neurobiology from Stanford University Howard Hughes Medical Institute. Vikram has an M.Sc. degree in Biochemistry from MS University Baroda.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Vikram Sudarsan invests in
Stages Vikram Sudarsan invests in
Countries Vikram Sudarsan invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 1 (100%)
- Health Care 1 (100%)
- Biotechnology 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Chase Pharmaceuticals (CPC) is engaged in the identification and clinical development of medically improved, commercially promising, treatments for central nervous system (CNS) disease. The Company was incorporated in 2007 to link emerging technical opportunities in the basic neurosciences to the expanding medical needs of those withneuropsychiatric disease. Operations thus focus on selecting product candidates to license-in, adding value by advancing towards global registration, and licensing-out to commercial partners. There success reflects an exceptional ability to select promising drug candidates, intimate knowledge of the development process as well as our ability to devise the most efficient path to regulatory approval.Since inception, CPC has sought to develop novel compounds that could improve the treatment of AD and related neurodegenerative disorders. Alzheimer’s disease constitutes the largest unmet medical need in neuropsychiatry. No emerging therapies have clearly demonstrated the potential to fulfill this medical need. Symptoms include an increasing loss of memory and other cognitive functions later combined with a variety of neuropsychiatric and behavioral disturbances. Progression is relentless, typically leading to death within 10 to 15 years. AD is now recognized as the third leading killer in the U.S. It is estimated that the 37 million afflicted worldwide cost society over $600 billion annually. As the population ages, this burden will rapidly climb to unsustainable levels. Although US sales of Alzheimer’s disease medications last year topped $4.7 billion, none of the current treatments improve symptoms more than marginally. Moreover, tolerability is poor, dose titration prolonged, and dropout rates high.Chase founders have invented and patented a unique combination of proven, currently marketed pharmaceuticals that we believe will benefit the symptomatic treatment of AD. | $21M / Series B / May 12, 2014 |
Co-Investors
About Cipla
Cipla is a drug manufacturing company that focuses on a variety of pharmaceutical products.
Cipla Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Naina Kidwai
Non-Executive Member of the Board of Directors
|
|||
|
Sahil Kumar
Manager Corporate Strategy
|
|||
Samina Vaziralli
Global Head - Strategy & New Ventures
|
|||
|
Vikram Sudarsan
Strategy Head - Cipla New Ventures - Cipla USA
|
|||
Y. K Hamied
Founder & Chairman
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Vikram Sudarsan invest in?
Vikram Sudarsan invests primarily in Medical, Health Care and Biotechnology startups, most often at Series B stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Vikram Sudarsan?
Public channels for Vikram Sudarsan include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Vikram Sudarsan last invest?
The most recent investment recorded for Vikram Sudarsan closed in May 2014. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
